The announced investment is not news, but rather an opportunity for Sanofi to drive France’s mRNA ambition as it lays the foundation stone at a production site in Lyon. Sanofi issued a press release (in French) this week announcing plans to invest €935 million ($1 billion) between 2022 and 2026 “in order to provide France with a complete and autonomous value chain in mRNA technology.” The announcement was made during the groundbreaking ceremony for Sanofi’s Evolutive Vaccines Facility (EVF) in…